相关实验视频

Updated: May 15, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

益生菌对动脉样硬化的潜在影响

Gerrit A Stuivenberg^1,2, Annabel Poon^1,2, Jeremy P Burton^1,2

¹Microbiology and Immunology, Western University, London N6A 3K7, Canada.

Microbiome research reports

|April 10, 2025

概括

益生菌可以通过减少与心血管风险相关的肠导尿毒素 (GDUTs) 来治疗动脉样硬化. 这种方法对于功能受损的患者来说是有前途的.

科学领域:

心血管医学心血管医学
微生物组研究微生物组研究
腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

动脉样硬化的发病率正在上升,这表明了解其病理生理学和治疗方面的差距.
人们越来越认识到肠道微生物组在动脉样硬化中的作用,肠道衍生尿素毒素 (GDUT) 是潜在的贡献者.
高血水平的GDUTs如三甲基胺 n-氧化物 (TMAO),p-cresyl硫酸盐和氧硫酸盐与功能减弱和心血管风险增加相关.

研究的目的:

审查益生菌在治疗动脉样硬化的潜力.
探索益生菌作为减少GDUTs的治疗策略.
为突出非传统风险因素或功能受损的患者的相关性.

主要方法:

对有关益生菌,肠道微生物组,GDUT和动脉样硬化的现有科学文献的审查.
在体外和体内研究的分析,证明了GDUTs的细菌清除.
专注于口服益生菌针对肠道的潜力.

主要成果:

一些有益的肠道细菌表现出代谢或清除GDUT的能力.
益生菌是一种可行的策略,可以调节肠道微生物群并降低循环中的GDUT水平.
通过益生菌向GDUT可以减轻动脉样硬化的进展.

结论:

减少循环GDUT是动脉样硬化患者潜在的治疗目标.
口服益生菌为降低GDUT和有利于动脉样硬化管理提供了一个有希望的途径.
这种方法对患有功能损失或异常动脉样硬化风险因素的人来说特别有前途.

关键词:

益生菌益生菌益生菌动脉样硬化动脉样硬化我们的肠道微生物群.尿源性毒素是一种毒素.

更多相关视频

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Prevention of Heat Stress Adverse Effects in Rats by Bacillus subtilis Strain

Prevention of Heat Stress Adverse Effects in Rats by Bacillus subtilis Strain

Published on: July 11, 2016

相关概念视频

Inflammation

Inflammation

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Factors Influencing Drug Absorption: Disease States and Pharmacology

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...